Good morning. Quite a bit of deal news to summarise this week across medtech and biotech. From a company developing devices to treat Alzheimer’s, through to genomics, gene therapies, and more. Congratulations to everyone and let me know if I missed anything.
➡️Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in $105m in an oversubscribed series C funding round.
➡️GSK buys 35Pharma for $950m, targeting next-generation pulmonary hypertension therapy and the TGF-β superfamily
➡️Paris-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier.
➡️BCI retinal implant medtech Science closes major $230M series C round
➡️Nvidia, the computer chip giant, continues its deep dive into expanding artificial intelligence technology in the medtech and cancer research arenas, this time with diagnostics maker Droplet Biosciences.
➡️Avisi Technologies: $10.7 Million Series A Raised To Advance Novel Glaucoma Device Development
➡️Sydney cancer medtech startup Lumonus, has added an additional $3 million to its Series B, four months on, to take the total raised to $28 million.
➡️Oxford-based immunology specialist Sitryx has entered into a new agreement with Boehringer Ingelheim aimed at advancing a novel small-molecule programme in autoimmune and inflammatory disease.
➡️Paris-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier.
➡️Lausanne-based Alithea Genomics has secured a total of CHF 6.9 million in seed financing to accelerate the commercialization of its high-throughput RNA sequencing kits for drug discovery and toxicology.
➡️Radiology firm RadNet is spending up to 230 million euros on Parisian imaging specialist Gleamer to create “the largest provider of radiology clinical AI solutions worldwide.”
➡️Medimaps and Radiobotics, two European medtechs are joining forces in a deal aimed at expanding their reach in the artificial-intelligence-enabled musculoskeletal imaging market and improving how doctors diagnose and treat osteoporosis and bone fractures.
➡️Genflow Biosciences , a biotech focused on gene therapies for age-related diseases, confirmed it has successfully raised £800,000 through a share subscription
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.